

# Stanford

---



## Sean Collins

Adjunct Clinical Assistant Professor, Medicine - Infectious Diseases

 Curriculum Vitae available Online

### CLINICAL OFFICES

- **Infectious Disease Clinic**

300 Pasteur Dr Rm L134

Lane Bldg MC 5107

Stanford, CA 94305

**Tel** (650) 723-9001      **Fax** (650) 568-1708

- **Positive Care Clinic**

211 Quarry Rd Ste 202

Palo Alto, CA 94304

**Tel** (650) 723-9001      **Fax** (650) 568-1708

### Bio

---

### CLINICAL FOCUS

- Infectious Disease
- HIV

### ADMINISTRATIVE APPOINTMENTS

- Senior Fellow, Stanford Center for Innovation in Global Health (CIGH), (2015- present)

### PROFESSIONAL EDUCATION

- HIV Specialist, AAHIVS, American Academy of HIV Medicine , HIV (2016)
- Board Certification: Infectious Disease, American Board of Internal Medicine (2014)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2011)
- Fellowship: Stanford University (2015) CA
- Residency: New York - Presbyterian Hospital / Weill Cornell Medical College (2011) NY
- Medical Education: Weill Cornell Medical College (2008) NY
- Masters of Science, Stanford University , Epidemiology and clinical research (2015)

### COMMUNITY AND INTERNATIONAL WORK

- Simplifying Hepatitis C Antiviral therapy in Rwanda for Elsewhere in the Developing world (SHARED), Rwanda
- Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir, Kigali, Rwanda

## Research & Scholarship

---

### CLINICAL TRIALS

- Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir, Not Recruiting

### Publications

---

#### PUBLICATIONS

- **Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.** *Journal of acquired immune deficiency syndromes (1999)*  
Hagins, D., Kumar, P., Saag, M., Wurapa, A. K., Brar, I., Berger, D., Osiyemi, O., Hileman, C. O., Ramgopal, M. N., McDonald, C., Blair, C., Andreatta, K., Collins, et al  
2021; 88 (1): 86-95
- **Long-term mortality after tuberculosis treatment among persons living with HIV in Haiti.** *Journal of the International AIDS Society*  
Joseph, Y., Yao, Z., Dua, A., Severe, P., Collins, S. E., Bang, H., Antoine Jean-Juste, M., Ocheretina, O., Apollon, A., McNairy, M. L., Dupnik, K., Cremieux, E., Byrne, et al  
2021; 24 (7): e25721
- **Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.** *Journal of acquired immune deficiency syndromes (1999)*  
Acosta, R. K., Willkom, M., Andreatta, K., Liu, H., Martin, R., Parvangada, A., Martin, H., Collins, S., White, K. L.  
2020; 85 (3): 363-371
- **Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.** *Lancet (London, England)*  
Mayer, K. H., Molina, J. M., Thompson, M. A., Anderson, P. L., Mounzer, K. C., De Wet, J. J., DeJesus, E., Jessen, H., Grant, R. M., Ruane, P. J., Wong, P., Ebrahimi, R., Zhong, et al  
2020; 396 (10246): 239-254
- **Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*  
Sax, P. E., Rockstroh, J. K., Luetkemeyer, A. F., Yazdanpanah, Y., Ward, D., Trottier, B., Rieger, A., Liu, H., Acosta, R., Collins, S. E., Brainard, D. M., Martin, H.  
2020
- **Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.** *The lancet. HIV*  
Orkin, C., DeJesus, E., Sax, P. E., Arribas, J. R., Gupta, S. K., Martorell, C., Stephens, J. L., Stellbrink, H. J., Wohl, D., Maggiolo, F., Thompson, M. A., Podzamczar, D., Hagins, et al  
2020; 7 (6): e389-e400
- **Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight** *PLOS ONE*  
McMahon, C., Trevaskis, J. L., Carter, C., Holsapple, K., White, K., Das, M., Collins, S., Martin, H., Burns-Naas, L.  
2020; 15 (2): e0229617
- **Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial** *LANCET HIV*  
Stellbrink, H., Arribas, J. R., Stephens, J. L., Albrecht, H., Sax, P. E., Maggiolo, F., Creticos, C., Martorell, C. T., Wei, X., Acosta, R., Collins, S. E., Brainard, D., Martin, et al  
2019; 6 (6): E364–E372
- **Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.** *The lancet. HIV*  
Wohl, D. A., Yazdanpanah, Y., Baumgarten, A., Clarke, A., Thompson, M. A., Brinson, C., Hagins, D., Ramgopal, M. N., Antinori, A., Wei, X., Acosta, R., Collins, S. E., Brainard, et al  
2019

- **Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials** *HIV MEDICINE*  
Hagins, D., Orkin, C., Daar, E. S., Mills, A., Brinson, C., DeJesus, E., Post, F. A., Morales-Ramirez, J., Thompson, M., Osiyemi, O., Rashbaum, B., Stellbrink, H., Martorell, et al  
2018; 19 (10): 724–33
- **Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide** *AIDS*  
Sax, P. E., DeJesus, E., Crofoot, G., Ward, D., Benson, P., Dretler, R., Mills, A., Brinson, C., Wei, X., Collins, S. E., Cheng, A.  
2018; 32 (12): 1723–25
- **Mass Spectrometric Identification of Urinary Biomarkers of Pulmonary Tuberculosis** *EBIOMEDICINE*  
Isa, F., Collins, S., Lee, M., Decome, D., Dorvil, N., Joseph, P., Smith, L., Salerno, S., Wells, M. T., Fischer, S., Bean, J. M., Pape, J. W., Johnson, et al  
2018; 31: 157–65
- **A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans.** *Open forum infectious diseases*  
Collins, S. E., Grant, P. M., Uwinkindi, F., Talbot, A., Seruyange, E., Slamowitz, D., Mugeni, A., Remera, E., Niyonsenga, S. P., Nyirimigabo, J., Uwizhiwe, J. P., Dongier, P., Muhayimpundu, et al  
2016; 3 (3): ofw141-?
- **Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients** *DRUGS*  
Collins, S. E., Grant, P. M., Shafer, R. W.  
2016; 76 (1): 75-98
- **Tuberculosis in the aftermath of the 2010 earthquake in Haiti** *BULLETIN OF THE WORLD HEALTH ORGANIZATION*  
Koenig, S. P., Rouzier, V., Vilbrun, S. C., Morose, W., Collins, S. E., Joseph, P., Decome, D., Ocheretina, O., Galbaud, S., Hashiguchi, L., Pierrot, J., Pape, J. W.  
2015; 93 (7): 498-502
- **CD4 deficit and tuberculosis risk persist with delayed antiretroviral therapy: 5-year data from CIPRA HT-001.** *international journal of tuberculosis and lung disease*  
Collins, S. E., Jean Juste, M. A., Koenig, S. P., Secours, R., Ocheretina, O., Bernard, D., Riviere, C., Calnan, M., Dunning, A., Hurtado Rúa, S. M., Johnson, W. D., Pape, J. W., Fitzgerald, et al  
2015; 19 (1): 50-57
- **Whole Genome Sequencing Investigation of a Tuberculosis Outbreak in Port-au-Prince, Haiti Caused by a Strain with a "Low-Level" rpoB Mutation L511P - Insights into a Mechanism of Resistance Escalation.** *PloS one*  
Ocheretina, O., Shen, L., Escuyer, V. E., Mabou, M., Royal-Mardi, G., Collins, S. E., Pape, J. W., Fitzgerald, D. W.  
2015; 10 (6)
- **Gender inequality and HIV transmission: a global analysis** *JOURNAL OF THE INTERNATIONAL AIDS SOCIETY*  
Richardson, E. T., Collins, S. E., Kung, T., Jones, J. H., Tram, K. H., Boggiano, V. L., Bekker, L., Zolopa, A. R.  
2014; 17
- **Correlation between Genotypic and Phenotypic Testing for Resistance to Rifampin in Mycobacterium tuberculosis Clinical Isolates in Haiti: Investigation of Cases with Discrepant Susceptibility Results** *PLOS ONE*  
Ocheretina, O., Escuyer, V. E., Mabou, M., Royal-Mardi, G., Collins, S., Vilbrun, S. C., Pape, J. W., Fitzgerald, D. W.  
2014; 9 (3)
- **Integrating integrase inhibitors into an antiretroviral regimen** *CURRENT TREATMENT OPTIONS IN INFECTIOUS DISEASES*  
Collins, S. E., Grant, P. M., Richardson, E. T., Zolopa, A. R.  
2014; 6 (2)
- **Outcomes of HIV-infected patients treated for recurrent tuberculosis with the standard retreatment regimen** *INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE*  
McGreevy, J., Juste, M. A., Severe, P., Collins, S., Koenig, S., Pape, J. W., Fitzgerald, D. W.  
2012; 16 (6): 841-845
- **High Mortality among Patients with AIDS Who Received a Diagnosis of Tuberculosis in the First 3 Months of Antiretroviral Therapy** *CLINICAL INFECTIOUS DISEASES*  
Koenig, S. P., Riviere, C., Leger, P., Joseph, P., Severe, P., Parker, K., Collins, S., Lee, E., Pape, J. W., Fitzgerald, D. W.

2009; 48 (6): 829-831

## **PRESENTATIONS**

- A Switch to Once Daily Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed HIV-infected Rwandans is Non-inferior to Continued Nevirapine-based Antiretroviral Therapy - 15th European AIDS Conference, Barcelona (October 21, 2015 - October 24, 2015)